<DOC>
	<DOCNO>NCT01122251</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy fix combination lercanidipine ( 10 mg 20 mg ) valsartan ( 80 mg 160 mg ) , lercanidipine valsartan alone reduce blood pressure . The study investigate dose response relationship combination monotherapies .</brief_summary>
	<brief_title>Efficacy Safety Lercanidipine Valsartan Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Lercanidipine</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Patients age 20 75 Essential hypertension screening ( 3 week ) Randomization Criteria : Essential hypertension baseline ( 90mmHg≤sitDBP≤109mmHg , except sitSBP≥180 ) Mean sitDBP≥110mmHg sitSBP≥180 Secondary hypertension suspect secondary hypertension Uncontrolled diabetes Severe heart disease severe cerebrovascular disease clinically significant hematological test result , renal disease ( serum creatinine ) liver disease ( ALT AST ) History malignant disease Autoimmune disease Women positive pregnancy test result , breast feeding intention pregnancy trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>hypertension</keyword>
	<keyword>lercanidipine</keyword>
	<keyword>valsartan</keyword>
</DOC>